Tobam Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tobam lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 10.8% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 944 shares of the biopharmaceutical company’s stock after selling 114 shares during the quarter. Tobam’s holdings in Regeneron Pharmaceuticals were worth $992,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brown Lisle Cummings Inc. raised its position in shares of Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10 shares during the period. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 10 shares in the last quarter. Adirondack Trust Co. increased its holdings in Regeneron Pharmaceuticals by 2.4% in the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares in the last quarter. UMB Bank n.a. raised its position in Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 10 shares during the period. Finally, Team Hewins LLC grew its position in shares of Regeneron Pharmaceuticals by 2.5% in the first quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 11 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 1.1 %

Regeneron Pharmaceuticals stock traded down $11.17 during mid-day trading on Thursday, hitting $1,001.02. The company’s stock had a trading volume of 260,407 shares, compared to its average volume of 492,523. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $110.35 billion, a PE ratio of 29.90, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. The stock’s fifty day moving average is $1,121.23 and its two-hundred day moving average is $1,038.27.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the previous year, the firm earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on REGN. Piper Sandler raised their price target on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a research note on Friday, August 23rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $1,300.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Truist Financial reissued a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. JPMorgan Chase & Co. lifted their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Finally, Barclays upped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,119.00.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.